NHS National Generic Pharmaceuticals - Wave 15a.
Offer reference number: CM/PHG/23/5697.
Period of framework agreement: The total maximum duration of the framework agreement to be no more than 28 months with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 48 months.
Potential periods of call-offs under the framework agreement:
CM/PHG/23/5697/01 – Orals (plus non-parenteral) Products:
All Regions (CESW/LSNE/NWLN): 01/02/2025 to 31/05/2027 (28 Months)
CM/PHG/23/5697/02 – Hospital Only Products:
DNW & DLN: 01/02/2025 to 31/01/2027 (24 months)
CM/PHG/23/5697/03 – Hospital Only Products (Housekeeping):
DLS & DNE: 01/02/2025 to 31/05/2026 (16 months)
DCE & DSW: 01/02/2025 to 30/09/2025 (8 months)
Potential periods of call-offs under the framework agreement:
CM/PHG/23/5697/01 – Orals (plus non-parenteral) Products:
All Regions (CESW/LSNE/NWLN): 01/02/2025 to 31/05/2027 (28 Months)
Potential periods of call-offs under the framework agreement:
CM/PHG/23/5697/02 – Hospital Only Products:
DNW & DLN: 01/02/2025 to 31/01/2027 (24 months)
Potential periods of call-offs under the framework agreement:
CM/PHG/23/5697/03 – Hospital Only Products (Housekeeping):
DLS & DNE: 01/02/2025 to 31/05/2026 (16 months)
DCE & DSW: 01/02/2025 to 30/09/2025 (8 months)